查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403342

治療診斷學市場至2030年的預測：按疾病類型、技術、最終用戶和地區進行的全球分析

Theranostics Market Forecasts to 2030 - Global Analysis By Disease Type (Neurological Disorder, Immunological Disorder, Cardiovascular Disease, Oncology and Other Disease Types), Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球治療診斷學市場規模為 7 億美元，預計到2030年將達到 17 億美元，預測期內年複合成長率為 11.8%。

名為「治療診斷學」的新醫學領域將治療方法和診斷結合成一個緊密結合的程序。 「治療診斷學」結合了「治療」和「診斷」，強調如何整合患者護理的兩個方面。它力求根據每位患者的獨特特徵和疾病概況提供精確、個體化的治療計劃。治療診斷學領域使用先進的診斷方法，如分子成像、基因檢測、生物標記分析和分子譜分析。

診斷技術的進步

分子影像、次世代定序（NGS）等先進診斷技術以及正子斷層掃描（PET）和磁振造影（MRI）等高解析度顯像模式提高疾病診斷的準確性和靈敏度。這種精確度使得能夠識別與疾病相關的特定生物標記、基因突變和分子標靶，這對於開發定製藥物的治療診斷學非常重要。此外，治療診斷學領域的早期識別允許快速介入和客製化治療計劃，透過允許更密集和強化的治療有可能改善患者的治療結果。

關於治療診斷學測試缺乏足夠的監管

在缺乏精確、明確的立法的情況下，治療診斷學測試的許可程序、驗證規範和品質標準都可能不清楚。這種不可預測性阻礙了新診斷方法的創建和使用，並可能延遲突破性藥物的上市。不確定的法律規範和不同的國際要求可能會延遲治療診斷學測試向市場的推出。公司可能難以通過複雜的監管程序，這可能導致核准等待時間更長並抑制市場成長。

加大舉措力度

研究和開發資金支持尖端診斷設備和技術的創建。這些進展將提高診斷測試的敏感性、特異性和準確性，能夠更精確地識別疾病生物標記、基因突變和分子標靶。治療診斷學在很大程度上依賴改進的診斷方法來指導客製化的治療計劃。治療診斷學產品和服務的擴展和商業化是由研發成果的市場成功推動的，為患者和醫療保健專業人員提供更個體化和高效的治療方法。

監管挑戰

新的治療診斷學測試和產品的推出可能會因嚴格的監管要求，複雜的核准程序和漫長的監管核准流程而推遲。這可能使患者難以按時接受個人化醫療和最尖端科技。由於核准程序和監管要求因地區而異，因此可能會出現市場碎片化。不同地理位置的監管要求不一致可能會導致治療診斷學測試的取得機會不平等，進而導致這些測試的可用性和採用率存在差異。

COVID-19 的影響

這次疫情爆發凸顯了快速、準確的診斷檢測的重要性。為了識別 SARS-CoV-2，PCR 和基於核酸擴增的檢測等分子診斷方法的使用急劇增加。對分子診斷方法的關注凸顯了類似方法在治療診斷學治療的其他疾病中的重要性。遠端醫療和遠端監控技術越來越受到青睞，以最大限度地減少親自就診並保持護理的連續性。這項變更可能會影響治療診斷學策略的實施方式，包括遠端監控和診斷。

預計神經系統疾病領域在預測期內將是最大的。

神經系統疾病領域預計將出現良好的成長，因為包括大腦、脊髓和周圍神經的多種疾病被稱為神經系統疾病。這些疾病包括多發性硬化症、癲癇、帕金森氏症、阿茲海默症和各種神經病變。此外，治療診斷學利用基因分析、分子生物標記和先進的影像方式來促進神經系統疾病的早期和準確識別。因此，準確的診斷儀器透過檢測與這些病理相關的特定生物標記和病理變化支持疾病追蹤和預後。

聚合酶鍊式反應（PCR）領域預計在預測期內年複合成長率最高

聚合酶鏈反應（PCR）領域預計在預測期內將以最高年複合成長率成長，特別是聚合酶鏈反應（PCR）對於診斷和預後應用非常重要。治療診斷學使用分子生物學技術聚合酶鍊式反應（PCR）來識別和擴增特定的 DNA 或 RNA 序列。 PCR是發現感染疾病、基因突變以及與各種疾病相關的生物標記的重要工具。基於 PCR 的補充診斷技術可以預測患者對特定治療的反應。因此，透過採用PCR分析特定的基因突變和生物標記物，醫療保健專業人員可以為每位患者選擇最合適的治療策略，並最大限度地提高治療效果。

佔有率最大的地區

預計北美在預測期內將佔據最大的市場佔有率。這是因為隨著北美越來越多的人患有癌症，對更有效和客製化的治療方法方案的需求日益成長。治療診斷學可以透過提供基於特定生物標記的標靶藥物來幫助更準確的癌症診斷和治療。此外，個人化醫療技術正變得越來越普及。因此，根據每位患者的基因組成、疾病特徵和生物標記來量身定做治療方法，推動市場成長。

年複合成長率最高的地區：

預計歐洲在預測期內的年複合成長率最高。這是因為癌症和其他慢性疾病的盛行率不斷上升，推動了對更個體化和有效治療方法的需求。治療診斷學因有望透過根據特定生物標記提供定製藥物來改善患者的治療效果而受到關注。在亞太地區，進行大量投資來加強醫療保健基礎設施，包括個人化醫療、分子診斷和先進成像技術計劃。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球治療​​診斷市場：依疾病類型

  • 神經病變
  • 免疫疾病
  • 循環系統疾病
  • 腫瘤學
    • 大腸直腸癌
    • 乳癌
    • 子宮頸癌
    • 肺癌
  • 其他疾病類型

第6章 全球治療​​診斷市場：依技術分類

  • 原位雜合反應
  • 聚合酶鍊式反應（PCR）
  • 免疫組織化學
  • 順序
  • 其他技術

第7章 全球治療​​診斷市場：依最終使用者分類

  • 診斷實驗室
  • 醫院和診所
  • 其他最終用戶

第8章 全球治療​​診斷市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter, Inc.
  • QIAGEN
  • Abbott Laboratories
  • Myriad Genetics, Inc.
  • Foundation Medicine, Inc.
  • AmeriPath, Inc.
  • Focus Diagnostics
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Leica Biosystems Nussloch GmBH
  • GE Healthcare
  • Pfizer, Inc.
Product Code: SMRC24567

According to Stratistics MRC, the Global Theranostics Market is accounted for $0.7 billion in 2023 and is expected to reach $1.7 billion by 2030 growing at a CAGR of 11.8% during the forecast period. A new area of medicine called "theranostics" blends therapeutic and diagnostic methods into a single, cohesive procedure. Combining the terms "therapy" and "diagnostics," "theranostics" emphasizes how both aspects of patient treatment should be integrated. It seeks to offer accurate and individualized treatment plans based on the unique traits and illness profiles of each patient. Advanced diagnostic methods such as molecular imaging, genetic testing, biomarker analysis, and molecular profiling are used in the field of theranostics.

Market Dynamics:

Driver:

Advancements in diagnostic technologies

The accuracy and sensitivity of illness diagnosis have been improved by sophisticated diagnostic technologies, such as molecular imaging, next-generation sequencing (NGS), and high-resolution imaging modalities including positron emission tomography (PET) and magnetic resonance imaging (MRI). The ability to identify certain biomarkers, genetic variants, or molecular targets linked to illnesses is made possible by this precision, and this is essential in theranostics for the development of tailored medicines. Moreover, early identification in the field of theranostics allows for prompt intervention and customized treatment plans, which may enhance patient outcomes by enabling more powerful and focused therapy.

Restraint:

Lack of properly defined regulations for theranostics tests

The clearance procedure, validation specifications, and quality criteria for theranostic testing might all be unclear in the absence of precise and defined laws. This unpredictability may impede the creation and use of novel diagnostics, delaying the release of ground-breaking theranostic products. Theranostic test market introduction may be delayed by unclear regulatory frameworks and disparate international requirements. Businesses may have trouble navigating complicated regulatory procedures, which might lead to longer wait times for clearances impeding the market growth.

Opportunity:

Increasing research and development initiatives

R&D expenditures support the creation of cutting-edge diagnostic instruments and technology. These developments improve diagnostic test sensitivity, specificity, and accuracy, making it possible to identify disease biomarkers, genetic variants, and molecular targets more accurately. Theranostics relies heavily on improved diagnostics to direct customized treatment plans. The expansion and commercialization of theranostic goods and services are facilitated by successful R&D outcomes on the market giving patients and healthcare professionals access to more individualized and efficient treatment alternatives.

Threat:

Regulatory challenges

New theranostic test and product launches might be delayed by onerous regulatory requirements, convoluted approval procedures, and protracted regulatory approval processes. This hold-up may make it more difficult for patients to receive individualized care and cutting-edge technologies on schedule. Market fragmentation may arise due to variations in approval procedures and regulatory requirements across different locations. Different geographic locations may experience unequal access to theranostic testing due to inconsistent regulatory requirements, which might lead to differences in the availability and uptake of these tests.

COVID-19 Impact

The epidemic brought to light how crucial quick and precise diagnostic testing is. The use of molecular diagnostic methods, such as PCR and assays based on nucleic acid amplification, has increased dramatically in order to identify SARS-CoV-2. The importance of comparable methods in treating other illnesses, such as those addressed by theranostics, has been highlighted by this focus on molecular diagnostics. In order to minimize in-person encounters and maintain continuity of treatment, telemedicine and remote monitoring technologies gained increasing traction. This change may affect how theranostics tactics that include remote monitoring and diagnostics are implemented.

The neurological disorder segment is expected to be the largest during the forecast period

The neurological disorder segment is estimated to have a lucrative growth, owing to a wide range of illnesses involving the brain, spinal cord, and peripheral nerves are referred to as neurological diseases. These illnesses include multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, and different neuropathies. Moreover, theranostics makes use of genetic profiling, molecular biomarkers, and sophisticated imaging methods to facilitate the early and precise identification of neurological illnesses. Thus, accurate diagnostic instruments support illness tracking and prognosis by detecting certain biomarkers or pathological alterations linked to these conditions.

The polymerase chain reaction (PCR) segment is expected to have the highest CAGR during the forecast period

The polymerase chain reaction (PCR) segment is anticipated to witness the highest CAGR growth during the forecast period, as polymerase chain reaction (PCR) is essential, particularly for diagnostic and prognostic uses. Theranostics uses polymerase chain reaction (PCR), a molecular biology technique, to identify and amplify specific DNA or RNA sequences. PCR is a vital tool for finding infections, genetic variants, and biomarkers linked to a variety of disorders. Complementary diagnostic techniques based on PCR can forecast how a patient will react to specific treatments. Hence healthcare professionals may choose the best course of action for each patient by employing PCR to analyze certain genetic variants or biomarkers, which maximizes therapeutic outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the need for more efficient and customized treatment choices that have grown as cancer cases become increasingly common in North America. Theranostics helps with more accurate cancer diagnosis and therapy by providing targeted medicines based on certain biomarkers. Moreover, personalized medicine techniques are becoming more and more popular. Thus, the goal is to customize therapies for each patient according to their genetic composition, illness features, and biomarkers driving the growth of the market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, as growing cancer and other chronic illness incidence has increased need for more individualized and efficient treatment alternatives. Theranostics attracted attention for its promise to enhance patient outcomes because of its capacity to provide tailored medicines based on certain biomarkers. The Asia Pacific area has seen significant investments in enhancing its healthcare infrastructure, encompassing projects in personalized medicine, molecular diagnostics, and sophisticated imaging technology.

Key players in the market:

Some of the key players profiled in the Theranostics Market include Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., QIAGEN, Abbott Laboratories, Myriad Genetics, Inc., Foundation Medicine, Inc., AmeriPath, Inc., Focus Diagnostics, Illumina, Inc., Agilent Technologies, Inc., Leica Biosystems Nussloch GmBH, GE Healthcare and Pfizer, Inc.

Key Developments:

In November 2023, Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List. The tests complete Roche's panel used for the differential diagnosis of acute viral hepatitis caused by the hepatitis A, B, C and E viruses.

In October 2023, Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics, and the transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.

In October 2023, Beckman Coulter Diagnostics, announced it acquired StoCastic, LLC. a leading artificial intelligence company that provides evidence-based decision support for hospital emergency departments (ED).

Disease Types Covered:

  • Neurological Disorder
  • Immunological Disorder
  • Cardiovascular Disease
  • Oncology
  • Other Disease Types

Technologies Covered:

  • In Situ Hybridization
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry
  • Sequencing
  • Other Technologies

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Theranostics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Neurological Disorder
  • 5.3 Immunological Disorder
  • 5.4 Cardiovascular Disease
  • 5.5 Oncology
    • 5.5.1 Colorectal Cancer
    • 5.5.2 Breast Cancer
    • 5.5.3 Cervical Cancer
    • 5.5.4 Lung Cancer
  • 5.6 Other Disease Types

6 Global Theranostics Market, By Technology

  • 6.1 Introduction
  • 6.2 In Situ Hybridization
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 Immunohistochemistry
  • 6.5 Sequencing
  • 6.6 Other Technologies

7 Global Theranostics Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Theranostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.8 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Hoffmann-La Roche Ltd
  • 10.2 Thermo Fisher Scientific Inc.
  • 10.3 Beckman Coulter, Inc.
  • 10.4 QIAGEN
  • 10.5 Abbott Laboratories
  • 10.6 Myriad Genetics, Inc.
  • 10.7 Foundation Medicine, Inc.
  • 10.8 AmeriPath, Inc.
  • 10.9 Focus Diagnostics
  • 10.10 Illumina, Inc.
  • 10.11 Agilent Technologies, Inc.
  • 10.12 Leica Biosystems Nussloch GmBH
  • 10.13 GE Healthcare
  • 10.14 Pfizer, Inc.

List of Tables

  • Table 1 Global Theranostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 4 Global Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 5 Global Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 6 Global Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 7 Global Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 8 Global Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 9 Global Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 10 Global Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 11 Global Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 12 Global Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 13 Global Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 14 Global Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 15 Global Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 16 Global Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 17 Global Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 18 Global Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 19 Global Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 20 Global Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 21 Global Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 22 North America Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 24 North America Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 25 North America Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 26 North America Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 27 North America Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 28 North America Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 29 North America Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 30 North America Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 31 North America Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 32 North America Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 33 North America Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 34 North America Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 35 North America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 36 North America Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 37 North America Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 38 North America Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 39 North America Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 North America Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 41 North America Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 42 North America Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Europe Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 45 Europe Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 46 Europe Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 47 Europe Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 48 Europe Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 49 Europe Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 50 Europe Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 51 Europe Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 52 Europe Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 53 Europe Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 54 Europe Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 55 Europe Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 56 Europe Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 57 Europe Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 58 Europe Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 59 Europe Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 60 Europe Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 61 Europe Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 62 Europe Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 63 Europe Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 64 Asia Pacific Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 66 Asia Pacific Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 67 Asia Pacific Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 68 Asia Pacific Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 69 Asia Pacific Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 70 Asia Pacific Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 71 Asia Pacific Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 72 Asia Pacific Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 73 Asia Pacific Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 74 Asia Pacific Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 75 Asia Pacific Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 76 Asia Pacific Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 77 Asia Pacific Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 78 Asia Pacific Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 79 Asia Pacific Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 80 Asia Pacific Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 81 Asia Pacific Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 82 Asia Pacific Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 83 Asia Pacific Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 84 Asia Pacific Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 85 South America Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 87 South America Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 88 South America Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 89 South America Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 90 South America Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 91 South America Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 92 South America Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 93 South America Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 94 South America Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 95 South America Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 96 South America Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 97 South America Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 98 South America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 99 South America Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 100 South America Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 101 South America Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 102 South America Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 103 South America Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 104 South America Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 105 South America Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 106 Middle East & Africa Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 107 Middle East & Africa Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 108 Middle East & Africa Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 109 Middle East & Africa Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 110 Middle East & Africa Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 111 Middle East & Africa Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 112 Middle East & Africa Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 113 Middle East & Africa Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 114 Middle East & Africa Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 115 Middle East & Africa Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 116 Middle East & Africa Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 117 Middle East & Africa Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 118 Middle East & Africa Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 119 Middle East & Africa Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 120 Middle East & Africa Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 121 Middle East & Africa Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 122 Middle East & Africa Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 123 Middle East & Africa Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 124 Middle East & Africa Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 125 Middle East & Africa Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 126 Middle East & Africa Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)